VLP-STING Agonist Program
Oncology (Immunotherapy non-responders)
PreclinicalActive
Key Facts
About Stimunity
Stimunity is a Paris-based, privately held biotech founded in 2016, focused on activating the innate immune system via the STING pathway. Its lead platform utilizes engineered virus-like particles (VLPs) designed to deliver STING agonists directly into target cells, aiming to overcome limitations of first-generation STING therapies. The company is in the preclinical stage, backed by €2M in seed funding from Portage Biotech and Horizon 2020 grants, and is led by a team with strong scientific and drug development expertise in immunology and oncology.
View full company profile